ClinConnect ClinConnect Logo
Search / Trial NCT06797856

Measurement of Refractive Error in Pseudophakic Eyes Using an Autorefractor and a Wavefront Aberrometer

Launched by JOHNSON & JOHNSON SURGICAL VISION, INC. · Jan 27, 2025

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how accurately two different tools, called an autorefractor and a wavefront aberrometer, can measure vision problems in people who have had cataract surgery and have an artificial lens implanted in one or both eyes. The goal is to understand how well these devices can help determine the correct prescription for glasses or contact lenses for individuals with a specific type of eye condition.

To participate in this study, you need to be at least 40 years old and have had cataract surgery with an artificial lens placed in at least one eye at least three months before joining. You should also meet certain vision requirements, such as having a stable prescription and good vision in your study eye. Throughout the trial, you'll undergo various tests, and all your information will be kept private. If you think you might be eligible and are interested in helping advance eye care, this could be a great opportunity!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria following Screening
  • The subject must:
  • 1. Read, understand, and sign the Statement of Informed Consent and HIPAA authorization and receive a fully executed copy of the form(s).
  • 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • 3. Be 40 years of age or older at the time of enrollment.
  • 4. Be pseudophakic in at least one eye, with that eye (hereafter referred to as the 'study eye') implanted with either the TECNIS Eyhance™ IOL (model ICB00, GIB00 or DIB00) or the TECNIS® Monofocal 1-Piece IOL (model ZCB00 or DCB00).
  • 5. Have had IOL surgery for the study eye completed at least 3 months prior to enrollment, with enough time elapsed between surgery and enrollment such that the refraction has stabilized in that eye.
  • Inclusion Criteria at Baseline Evaluation
  • The subject must:
  • 6. In the study eye, meet the following criteria with regard to the non-vertex-corrected (i.e., spectacleplane) distance subjective refraction:
  • 1. Mean spherical equivalent must be between +2.00 and -2.00 DS (inclusive).
  • 2. The magnitude of the cylinder must be 1.50 DC or less.
  • 7. Have best-corrected visual acuity of at least 20/32 in the study eye.
  • Exclusion Criteria following Screening
  • The subject must not:
  • 1. Be pregnant.
  • 2. Have uncontrolled diabetes by self-report.
  • 3. Have a history of ocular trauma, systemic disease or medication use known to cause variability in refractive error.
  • 4. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.) other than bilateral cataract surgery with IOL implantation and YAG laser capsulotomy.
  • 5. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, scleral lenses, or hybrid lenses (e.g., SynergEyes, SoftPerm) within the past 3 months.
  • 6. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site or study Sponsor.
  • 7. Be taking any ocular or systemic medications known to adversely affect vision or cause miosis, or that may otherwise compromise study endpoints.
  • 8. Be currently participating in or have participated in any other clinical trial within 30 days prior to enrollment. Exclusion Criteria at Baseline Evaluation
  • The subject must not:
  • 9. Have clinically significant slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities, or bulbar injection) or other corneal or ocular disease or abnormalities that, in the opinion of the investigator, may compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, corneal scar or opacity ≥ 0.3 mm, recurrent corneal erosions, moderate or above corneal distortion, herpetic keratitis).
  • 10. Have posterior capsular opacification (PCO) that, in the opinion of the investigator, is significant enough that it is likely to detrimentally affect autorefraction or wavefront measurements. 11. Have fluctuations in vision due to clinically significant dry eye. 12. Have a history of strabismus, amblyopia, nystagmus, or any condition that affects fixation.

About Johnson & Johnson Surgical Vision, Inc.

Johnson & Johnson Surgical Vision, Inc. is a leading global company dedicated to advancing the field of ophthalmic surgery through innovative technologies and solutions. As a subsidiary of Johnson & Johnson, it specializes in the development and commercialization of products for cataract and refractive surgery, focusing on improving patient outcomes and enhancing surgical precision. With a commitment to research and development, the company collaborates with healthcare professionals to deliver cutting-edge medical devices and instrumentation that address the evolving needs of eye care providers and their patients.

Locations

Long Beach, California, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported